Literature DB >> 2177454

CMV encephalitis during ganciclovir therapy of CMV retinitis.

T F Schwarz1, K Loeschke, I Hanus, G Jäger, W Feiden, F H Stefani.   

Abstract

An AIDS patient with cytomegalovirus (CMV) retinitis was treated with ganciclovir (10 mg/kg) for four days followed by 5 mg/kg for 69 days. Clinically, CMV retinitis improved during therapy. Two weeks after induction of therapy, the patient became increasingly disoriented, and died 78 days after admission. Microscopically, a necrotizing encephalitis with characteristic cytomegalic cells with intranuclear inclusion bodies was observed. We conclude that ganciclovir therapy did not prevent development or progression of CMV encephalitis in the doses used.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177454     DOI: 10.1007/BF01647008

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus.

Authors:  O L Laskin; D M Cederberg; J Mills; L J Eron; D Mildvan; S A Spector
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

2.  Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies.

Authors: 
Journal:  N Engl J Med       Date:  1986-03-27       Impact factor: 91.245

3.  Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group.

Authors:  G N Holland; R F Sison; D E Jatulis; M G Haslop; M J Sakamoto; N C Wheeler
Journal:  Ophthalmology       Date:  1990-02       Impact factor: 12.079

4.  Therapy for cytomegalovirus polyradiculomyelitis in patients with AIDS: treatment with ganciclovir.

Authors:  J de Gans; P Portegies; G Tiessens; D Troost; S A Danner; J M Lange
Journal:  AIDS       Date:  1990-05       Impact factor: 4.177

5.  Multifocal cytomegalovirus encephalitis in AIDS.

Authors:  J C Masdeu; C B Small; L Weiss; C M Elkin; J Llena; R Mesa-Tejada
Journal:  Ann Neurol       Date:  1988-01       Impact factor: 10.422

6.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

  6 in total
  7 in total

1.  Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS.

Authors:  C Mussini; N Mongiardo; G Manicardi; F Trenti; A Alessandrì; F Paolillo; A Catania; M Portolani; M Pecorari; V Borghi; G Ficarra; A Cossarizza; B De Rienzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

2.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.

Authors:  J Neyts; H Sobis; R Snoeck; M Vandeputte; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

3.  [Progressive cytomegalovirus encephalitis in successful ganciclovir therapy of cytomegalovirus retinitis in an AIDS patient].

Authors:  S Ewig; E Bierhoff; W Luster; A Steudel; D Niese
Journal:  Klin Wochenschr       Date:  1991-07-22

Review 4.  Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.

Authors:  M Peters; U Timm; D Schürmann; H D Pohle; B Ruf
Journal:  Clin Investig       Date:  1992-05

5.  Early diagnosis and successful treatment of acute cytomegalovirus encephalitis in a renal transplant recipient.

Authors:  S Bamborschke; T Wullen; M Huber; M Neveling; C A Baldamus; K Korn; G Jahn
Journal:  J Neurol       Date:  1992-04       Impact factor: 4.849

Review 6.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

7.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.